Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate leaves FTC provision off finance reform

This article was originally published in The Tan Sheet

Executive Summary

A congressional conference committee will decide whether to include a provision in financial services reform legislation provision that dramatically expands the Federal Trade Commission's rulemaking authority. The Senate passed a version of the Wall Street Reform and Consumer Protection Act, H.R. 4173, without a provision the House included that amends the FTC Act by removing procedural requirements from the commission's rulemaking and enforcement capabilities (1"The Tan Sheet" April 26, 2010). Dietary supplement industry trade groups and other industry organizations lobbied against the provision that would enable FTC to adopt trade regulations using the Administrative Procedure Act rulemaking procedure and no longer require the agency to obtain congressional approval before undertaking formal rulemaking procedures. The House and Senate will appoint conference committee members to negotiate a final bill that resolves differences over the FTC provision and other sections of the extensive legislation

You may also be interested in...

FTC Provision In Finance Reform Bill Could Bite Supplement Firms

Dietary supplement trade groups join a wide swath of industries telling Congress a minor provision of extensive financial services reform legislation would give the Federal Trade Commission nearly unfettered rulemaking authority

QUOTED. 28 January 2020. Steven Falowski.

Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts